# Microbot Medical Inc.

**MBOT**

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000883975

# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $81.5M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, short runway, thin data<br>not computable: fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 26, 2026<br>220 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $1.09<br>2026-10-30; market equity $73.2M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 26, 2026*

is a medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. We are primarily focused on leveraging our robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. our LIBERTY® technological platform, we have developed the first-ever fully disposable robot for various endovascular interventional procedures. The LIBERTY® Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body's vasculature.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 80.9** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |

*latest aligned inputs end 2013-12-31; latest annual assets end 2025-12-31*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (0.2%) | (6.6%) | | 80.9 | 803 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 3* | | | | | | |
| **Solvency, sleeve percentile 8.0** | | | | | | |
| Twelve-month failure probability | 0.03% | 0.08% | | 18.4 | 246 | 2026-06-30 |
| Altman Z double-prime | 21.18 | (0.35) | | 2.5 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 23.33x | 2.92x | | 3.0 | 829 | 2025-12-31 |
| **Growth and financing, sleeve percentile 42.0** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four consecutive annual observations are required* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *required facts have no common fiscal period end* | | | | | | |
| Asset growth, three years | 104.5% | 2.2% | | 2.0 | 696 | 2025-12-31 |
| Net share issuance, one year | 93.3% | 2.5% | | 81.9 | 631 | 2026-03-24 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 93.3% |
| Short runway | cash runway is 2.1 months |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (46.2%) | (2.2%) | 18 |
| Distance from 52-week high | (61.8%) | (28.7%) | 19 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | (17.9%) | (1.0%) | 25 |
| Book value to price | 0.94 | 0.28 | 84 |
| Sales to price | 0.00 | 0.30 | 3 |
| Composite equity issuance, five years | 224.6% | 20.5% | 92 |
| Relative strength against the sector, log excess return | (0.79) | (0.19) | 18 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $3.2M |
| Operating cash flow, four quarters | -$17.6M |
| Months of runway | 2.1 |
| Days since last periodic filing | 82 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $750,237 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $886,642 | 2013-12-31 | 2014-03-13 | 10-K | 14-097773 |
| 2 | assets | us-gaap:Assets | $41.6M | 2013-12-31 | 2015-03-13 | 10-K | 15-091382 |
| 3 | net income | us-gaap:NetIncomeLoss | -$13.1M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$13.0M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 5 | assets | us-gaap:Assets | $81.5M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 6 | assets | us-gaap:Assets | $6.0M | 2024-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 7 | current assets | us-gaap:AssetsCurrent | $79.8M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $3.4M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$104.1M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$14.7M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 11 | book equity | us-gaap:StockholdersEquity | $77.6M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 12 | liabilities | us-gaap:Liabilities | $4.0M | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 13 | operating income | us-gaap:OperatingIncomeLoss | $5.3M | 2017-12-31 | 2019-04-01 | 10-K | 19-004545 |
| 14 | interest expense | us-gaap:InterestAndDebtExpense | -$2.3M | 2017-12-31 | 2018-04-02 | 10-K | 18-004562 |
| 15 | revenue | us-gaap:Revenues | $116,887 | 2015-12-31 | 2016-03-15 | 10-K | 16-504472 |
| 16 | revenue | us-gaap:Revenues | $172,297 | 2013-12-31 | 2016-03-15 | 10-K | 16-504472 |
| 17 | revenue | us-gaap:Revenues | $1.4M | 2012-12-31 | 2014-03-13 | 10-K | 14-097773 |
| 18 | revenue | us-gaap:Revenues | $1.2M | 2011-12-31 | 2014-03-13 | 10-K | 14-097773 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $60,000 | 2025-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.8M | 2024-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $25,000 | 2024-12-31 | 2026-03-26 | 10-K | 26-012935 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.5M | 2023-12-31 | 2025-03-25 | 10-K | 25-000614 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $33,000 | 2023-12-31 | 2025-03-25 | 10-K | 25-000614 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$11.5M | 2022-12-31 | 2024-03-27 | 10-K | 24-011521 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $84,000 | 2022-12-31 | 2024-03-27 | 10-K | 24-011521 |
| 26 | assets | us-gaap:Assets | $8.3M | 2023-12-31 | 2025-03-25 | 10-K | 25-000614 |
| 27 | assets | us-gaap:Assets | $9.5M | 2022-12-31 | 2024-03-27 | 10-K | 24-011521 |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 67,158,044 | 2026-03-24 | 2026-03-26 | 10-K | 26-012935 |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 34,744,476 | 2025-03-24 | 2025-03-25 | 10-K | 25-000614 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.